Entero Healthcare Solutions Ltd
₹ 1,196
0.88%
29 May
- close price
About
Incorporated in 2018, Entero Healthcare
Solutions Ltd is in the business of distribution
and marketing of pharmaceutical and surgical products and allied services[1]
Key Points
- Market Cap ₹ 5,204 Cr.
- Current Price ₹ 1,196
- High / Low ₹ 1,390 / 944
- Stock P/E 43.6
- Book Value ₹ 388
- Dividend Yield 0.00 %
- ROCE 10.6 %
- ROE 6.99 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 57.5% CAGR over last 5 years
Cons
- Stock is trading at 3.08 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 6.07% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 1,350 | 1,773 | 2,522 | 3,300 | 3,922 | 5,096 | 6,591 | |
| 1,326 | 1,758 | 2,498 | 3,236 | 3,810 | 4,924 | 6,325 | |
| Operating Profit | 23 | 15 | 24 | 64 | 112 | 172 | 266 |
| OPM % | 2% | 1% | 1% | 2% | 3% | 3% | 4% |
| 5 | 11 | 4 | 6 | 14 | 39 | 11 | |
| Interest | 13 | 20 | 29 | 49 | 66 | 42 | 54 |
| Depreciation | 12 | 16 | 20 | 24 | 25 | 31 | 43 |
| Profit before tax | 4 | -11 | -20 | -4 | 36 | 139 | 179 |
| Tax % | 67% | 42% | 49% | 201% | -12% | 23% | 19% |
| 1 | -15 | -29 | -11 | 40 | 107 | 146 | |
| EPS in Rs | 93.81 | -1,550.90 | -77.71 | -28.12 | 8.99 | 21.79 | 26.44 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 26% |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 57% |
| 3 Years: | 131% |
| TTM: | 26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| Last Year: | 7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 4 | 4 | 43 | 44 | 44 |
| Reserves | -16 | -32 | -62 | -73 | 1,595 | 1,681 | 1,645 |
| 603 | 720 | 974 | 1,101 | 338 | 385 | 677 | |
| 162 | 147 | 210 | 275 | 369 | 593 | 1,234 | |
| Total Liabilities | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 3,600 |
| 186 | 189 | 262 | 268 | 289 | 559 | 960 | |
| CWIP | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 58 | 130 |
| 560 | 645 | 863 | 1,040 | 2,056 | 2,085 | 2,510 | |
| Total Assets | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 3,600 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| -37 | -69 | -35 | -45 | -37 | -77 | 96 | |
| -203 | -31 | -162 | -49 | -704 | 232 | -303 | |
| 217 | 89 | 211 | 73 | 863 | -74 | 124 | |
| Net Cash Flow | -23 | -11 | 14 | -21 | 122 | 82 | -83 |
| Free Cash Flow | -81 | -78 | -45 | -51 | -41 | -87 | 29 |
| CFO/OP | -134% | -430% | -100% | -51% | -21% | -23% | 36% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 63 | 50 | 54 | 57 | 57 | 59 | 67 |
| Inventory Days | 57 | 54 | 49 | 41 | 43 | 52 | 52 |
| Days Payable | 32 | 22 | 22 | 25 | 24 | 31 | 45 |
| Cash Conversion Cycle | 88 | 82 | 81 | 73 | 77 | 80 | 74 |
| Working Capital Days | 57 | 54 | 41 | 32 | 48 | 65 | 42 |
| ROCE % | 1% | 1% | 5% | 7% | 9% | 11% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Healthcare Product Manufacturer Relationships Number |
|
||||
| Number of Districts Covered Number |
|||||
| Number of Hospital Customers Number |
|||||
| Number of Retail Pharmacy Customers Number |
|||||
| Number of SKUs Handled Number |
|||||
| Number of Warehouses Number |
|||||
| Total Warehouse Area Sq. Ft. |
|||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Clarification On Investor Queries Relating To Profit Attributable To Owners Of The Company And Minority Interest For The Quarter Ended 31St March 2026
1d - Clarifies Q4 FY26 profit was hit by INR 114 million one-off costs and Anand Chemiceutics acquisition raised minority interest.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
2d - Entero Healthcare filed FY26 secretarial compliance report; minor prior LODR delays and fines noted.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Newspaper publication for Audited Financial Results of the Company for the Quarter and Year ended March 31, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
26 May - Audio recording of FY26 audited results earnings call uploaded; transcript to follow.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
25 May - Investor Presentation for Audited Financial Results/Statements for the Quarter and Financial Year ended March 31, 2026.
Concalls
-
May 2026TranscriptPPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT
-
Feb 2025TranscriptPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptAI SummaryPPT
-
Mar 2024Transcript PPT
Business Overview:[1]
EHSL, a leading Healthcare Supply Chain Solutions Specialist, ranks among India’s top three healthcare product distributors by revenue, offering demand fulfillment and generation solutions to manufacturers.